Hoover R David's Form 4 filing
Elanco Animal Health Inc (ELAN) · filed Mar 2, 2022
- Accession no.
- 0001179110-22-001943
- Filed
- Mar 2, 2022
- Trade date
- Feb 28-Mar 2, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market purchases total $288.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hoover R DavidCIK 0001186033 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Reflects the weighted average price of 5,000 shares of common stock of Elanco Animal Health Inc. purchased by the reporting person in multiple transactions on March 1, 2022 with purchase prices ranging from $28.43 to $28.899 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
Referenced by the price of 1 transaction in Table I.
- F2
Reflects the weighted average price of 5,000 shares of common stock of Elanco Animal Health Inc. purchased by the reporting person in multiple transactions on March 2, 2022 with purchase prices ranging from $28.88 to $29.12 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
Referenced by the price of 1 transaction in Table I.
- F4
The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan.
Referenced by the price of 1 transaction in Table II.
- F5
The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $28.41 on February 28, 2022.
Referenced by the price of 1 transaction in Table II.
Remarks
Chairman of the Elanco Board of Directors